How to buy ProQR Therapeutics BV stock (PRQR)

ProQR Therapeutics BV is a biotechnology business based in the US. ProQR Therapeutics BV shares (PRQR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.63 – a decrease of 7.07% over the previous week. ProQR Therapeutics BV employs 156 staff and has a trailing 12-month revenue of around $18.4 million.

Our top picks for where to buy ProQR Therapeutics BV stock

Buy ProQR Therapeutics BV stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

ProQR Therapeutics BV stock price (NASDAQ: PRQR)

Use our graph to track the performance of PRQR stocks over time.

ProQR Therapeutics BV shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$2.63
52-week range	$1.61 - $4.62
50-day moving average more info button	$3.40
200-day moving average more info button	$2.31
Wall St. target price	$8.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.31

Is it a good time to buy ProQR Therapeutics BV stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ProQR Therapeutics BV price performance over time

Historical closes compared with the close of $2.59 from 2024-12-19

1 week (2024-12-13)	-8.48%
1 month (2024-11-21)	-28.25%
3 months (2024-09-20)	49.71%
6 months (2024-06-21)	51.46%

1 year (2023-12-21)	28.86%
2 years (2022-12-21)	56.97%
3 years (2021-12-21)	8
5 years (2019-12-20)	9.4

ProQR Therapeutics BV financials

Revenue TTM	$18.4 million
Gross profit TTM	$4.8 million
Return on assets TTM	-14.86%
Return on equity TTM	-67.14%
Profit margin	-130.21%
Book value	$0.31
Market Capitalization more info button	$272.2 million

TTM: trailing 12 months

ProQR Therapeutics BV share dividends

We're not expecting ProQR Therapeutics BV to pay a dividend over the next 12 months.

ProQR Therapeutics BV share price volatility

Over the last 12 months, ProQR Therapeutics BV's shares have ranged in value from as little as $1.61 up to $4.62. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ProQR Therapeutics BV's is 0.253. This would suggest that ProQR Therapeutics BV's shares are less volatile than average (for this exchange).

ProQR Therapeutics BV overview

ProQR Therapeutics N. V. , a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.

Frequently asked questions

What percentage of ProQR Therapeutics BV is owned by insiders or institutions?
Currently 14.495% of ProQR Therapeutics BV shares are held by insiders and 24.958% by institutions. How many people work for ProQR Therapeutics BV?
Latest data suggests 156 work at ProQR Therapeutics BV. When does the fiscal year end for ProQR Therapeutics BV?
ProQR Therapeutics BV's fiscal year ends in December. Where is ProQR Therapeutics BV based?
ProQR Therapeutics BV's address is: Zernikedreef 9, Leiden, Netherlands, 2333 CK What is ProQR Therapeutics BV's ISIN number?
ProQR Therapeutics BV's international securities identification number is: NL0010872495 What is ProQR Therapeutics BV's CUSIP number?
ProQR Therapeutics BV's Committee on Uniform Securities Identification Procedures number is: N71542109